SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Indications -- Hepatitis
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: DewDiligence_on_SI1/31/2008 5:46:00 PM
   of 312
 
Baraclude has surpassed Hepsera as the leading HBV drug in worldwide sales:

4Q07 Baraclude sales: $99M, +175% (!) vs 4Q06 and +38% vs 3Q07.

$70M of the $99M came from outside the US; this number was boosted to some degree by currency.

biz.yahoo.com

Hepsera has plateaued at an annual run rate of about $300M and it can be expected to become less and less of a factor in the HBV market, especially when Viread is launched later this year.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News